Streetbeat News

Regulatory

APLS

BIOVF

Apellis Pharmaceuticals and Swedish Orphan Biovitrum released positive Phase 3 study results for pegcetacoplan in treating rare kidney diseases. The study met its primary endpoint, showing a significant reduction in proteinuria. Both companies plan to submit marketing applications in 2025.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 4:53 pm

FXNC

TSBA

First National Corporation (NASDAQ: FXNC) and Touchstone Bankshares (OTCPK: TSBA) have received regulatory approvals for their merger, expected to close in Q4 2024. The combined entity will have approximately $2.1 billion in assets, $1.8 billion in deposits, and $1.5 billion in loans.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 4:36 pm

ALDX

Aldeyra Therapeutics Inc. (NASDAQ: ALDX) announced that its Phase 3 clinical trial for the dry eye drug reproxalap met its primary endpoint, showing significant improvement in ocular discomfort. The study's success has led to a 34.8% increase in ALDX stock price. The company plans to resubmit its New Drug Application (NDA) to the FDA in 2024, with a review period expected to last six months.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 4:30 pm

AAPL

AMZN

GOOG

META

MSFT

NVDA

QQQ

SPY

TBT

TLT

TSLA

The article discusses the impact of a weak Treasury auction and jobless claims on the stock market. It highlights the importance of monitoring the S&P 500 ETF (SPY) and Nasdaq 100 ETF (QQQ), as well as the Magnificent Seven stocks (AAPL, AMZN, GOOG, META, MSFT, NVDA, TSLA). The Bank of Japan's hawkish stance and the weak Treasury auction have led to market volatility. Investors are advised to consider protection bands and focus on high-quality bonds.

Portfolio Pulse from The Arora Report

August 08, 2024 | 4:25 pm

SNY

Sanofi SA (NASDAQ:SNY) reported positive results from the GMMG-HD7 phase 3 study of Sarclisa in combination with other drugs for treating multiple myeloma. The study showed significant improvement in progression-free survival. The FDA has accepted a supplemental Biologics License Application for Sarclisa, with a decision expected by September 27, 2024.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 4:23 pm

AAPL

VGK

Apple has announced changes to its App Store terms, allowing developers to offer products outside of its ecosystem. This move comes in response to an EU announcement. The changes could impact Apple's revenue from its App Store and may influence the broader tech market.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 4:17 pm

MGRM

Monogram Technologies shares are trading higher after the company announced that it has submitted a premarket filing to the FDA for its mBôs TKA System.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 3:51 pm

MRK

RHHBY

Merck & Co Inc (NYSE:MRK) has discontinued its Phase 3 KeyVibe-008 trial for a Keytruda combination due to ineffective results and higher adverse events. The trial compared the combination to Roche's Tecentriq for treating extensive-stage small cell lung cancer. Merck is notifying investigators and offering alternative treatments. The stock is up 0.82% following the announcement.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 3:51 pm

GOVX

INO

MRNA

SIGA

Africa CDC is planning to declare the regional Mpox outbreak an emergency, which could have significant implications for companies involved in vaccine and treatment development.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 3:45 pm

CUBI

SPY

Customers Bancorp must enhance its risk management practices for its digital asset strategy under a written agreement with the Federal Reserve. The Fed's Aug. 5 enforcement action revealed issues during a regular examination. The company must submit a plan to improve its BSA and AML compliance, including policies, procedures, and controls to ensure accurate information collection and retention for all customers.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 3:28 pm